Clinical Research Directory
Browse clinical research sites, groups, and studies.
Intermittent Preventive Treatment of Malaria in School-age Children to Decrease Community Transmission
Sponsor: University of California, San Francisco
Summary
The CRITICal study aims to estimate the effectiveness of intermittent preventive treatment in school children (IPTsc) with dihydroartemisinin-piperaquine (DP) for reducing community level malaria burden. Given that school-aged children are the primary drivers of transmission, the study hypothesis is that IPTsc will reduce this infectious reservoir and thus the burden of malaria in persons of all ages in surrounding communities.
Official title: Cluster Randomized Trial of Intermittent Preventive Treatment of Malaria in School-age Children to Improve the Health of Students and Decrease Community Transmission
Key Details
Gender
All
Age Range
Any - 17 Years
Study Type
INTERVENTIONAL
Enrollment
4800
Start Date
2026-05-01
Completion Date
2029-05-31
Last Updated
2026-01-20
Healthy Volunteers
Yes
Conditions
Interventions
dihydroartemisinin-piperaquine
D-Artepp, is manufactured by Guilin Pharmaceutical Co Ltd, and is prequalified by the WHO and approved for use in Uganda by the National Drug Authority. Standard treatment doses of DP (once a day x 3 days) will be administered using weight-based guidelines targeting a total dose of 6.4 mg/kg dihydroartemisinin and 51.2 mg/kg of piperaquine as per manufacturer's instructions.
Locations (1)
Infectious Diseases Research Collaboration
Kampala, Uganda